Talking Tox, and Changing Drug Development | GenomeWeb

Oh, the memories of my earliest days here at Genome Technology. As a journalist new to the field of genomics, I was intrigued to hear about the promise of it all: the impact it would have on medical treatment, drug discovery and development — well, you remember. Too much hype led to the bubble burst, and all of us have been understandably skeptical since then of sweeping claims (and sometimes any claims at all) made about the impact of genomics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.